Kymera's KT-621 shows promising STAT6 degradation in Phase 1 trials, with favorable safety and planned further studies in 2025. KT-621 demonstrated superior Th2 biomarker reductions compared to ...
Terns Pharmaceuticals announced significant updates regarding TERN-601, a novel oral GLP-1R agonist, following a successful Phase 1 clinical study and the completion of enrollment in its Phase 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results